

ABSTRACT TOPICS:

INSULIN THERAPY AND TECHNOLOGIES IN TREATING DIABETES TYPE 1 AND 2 TREATMENT

RULES OF SUBMISSION:

Please follow these rules carefully. Failure to comply with abstract submission rules will result in your abstract not being accepted for review.

Please note that the rules set out below apply to delegate's abstract submission only. Invited speakers should refer to instructions provided directly from the Conference Secretariat for the submission of abstracts for invited speakers.

- Submission of abstracts describing data that has previously been published in any scientific journal is not permitted.
- The multiple submissions of abstracts describing different components of the same study are not appropriate. Whenever possible, all findings generated from the same study should be included in a single abstract.
- Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
- Abstracts containing data considered to be insufficiently informative may be accepted but published by title only. In the latter event, the Scientific Advisory Committee will inform the presenting author that the abstract contained insufficient data. Its acceptance (with publication by title only) may be conditional upon receipt of a statement in which the author(s) explain how an informative data set will become available for presentation by the time of the Conference.
- Use a concise title that indicates the content of the abstract. The title should not exceed 250 characters. Avoid using abbreviations in the title.
- The first name in each abstract should be that of the presenting author.
- Submission of more than one abstract by the same first author is not allowed.
- Each author is permitted to present at the conference only once. Please note however, that invited speakers may submit abstracts for consideration for platform/poster sessions.
- Institution information should be provided for all authors. Include institution, city, state/province and country but do not include department, division, laboratory, etc.
- Abstracts should be structured in 4 sections:
 - Purpose
 - Method
 - Result
 - Conclusion
- The "Purpose" section should briefly indicate the objectives of the work being presented. The "Method" section should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures. The "Result" section should summarize the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals. The "Conclusion" section should state briefly the conclusions reached in the work.
- Abstracts should be no longer than 250 words in length (this limit excludes the abstract title, authors and institutions but includes references).

- Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
- Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis.
- References should be used sparingly. They should be included within the text in brackets. For journals, mention first author "et al" followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages.
- Figures, tables and other illustrations should not be included in abstracts.
- Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.
- If the work was supported by funds provided by a commercial company this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
- All abstract submissions for Poster/Platform presentations must be submitted via the on-line abstract submission system.
- Abstracts submitted via fax and email will not be accepted for review.
- Abstracts will not be accepted unless they are submitted according to the rules, instructions and format described and received by the Conference Secretariat on or before 01.Dec.2009.Late abstracts will NOT be accepted.
- Abstracts will be accepted and receive final acceptance only if the presenting author has registered for the Conference before submitting the abstract.
- Authors will be notified regarding Abstract acceptance. Accepted abstracts will be printed in the Book of Abstracts that will be distributed at the Conference. Only a limited number of abstracts will be scheduled for oral and poster presentation. Please indicate if you are submitting yours abstract for oral or poster presentation. Authors will be notified of the method of presentation.
- Instructions for both oral and poster presentations will be e-mailed with notices of acceptance. Please note that authors selected for poster presentation may be required to submit the poster for display in both electronic and traditional poster format.
- Among submitted and accepted abstracts Scientific Committee of ADiT will select 2 best abstracts for »ADiT best abstracts 2009« award, one from India and one worldwide.
- Award of 1000 Euro each will be handed to authors at Closing ceremony.Awarded abstracts will be published as first and second (by alphabetical order- author's surname) in ADiT 2009 Abstract book along with short author's introduction and photo.
- Upon deciding about the awarded abstracts following rules will be taken into consideration :
 - Geographical
 - Scientific or clinical value of work and research
 - Uniqueness and novelty of abstract thesis
 - Practical value of abstract to clinical practice in diabetes treatment